公开(公告)号：AU636608B2

公开(公告)日：1993-05-06

申请号：AU5514190

申请日：1990-05-17

Applicant: YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED

Inventor： DAVID WALLACH ,  HARMUT ENGELMANN ,  DAN ADERKA ,  DANIELA NOVICK ,  MENACHEM RUBINSTEIN

IPC: G01N33/53 ,  A61K38/00 ,  A61K38/17 ,  A61K38/19 ,  A61K39/395 ,  A61P37/00 ,  C07K1/14 ,  C07K1/16 ,  C07K1/20 ,  C07K1/22 ,  C07K7/06 ,  C07K14/00 ,  C07K14/435 ,  C07K14/46 ,  C07K14/47 ,  C07K14/52 ,  C07K14/525 ,  C07K14/715 ,  C07K16/00 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/28 ,  C12N15/63 ,  C12P21/00 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C12R1/91 ,  G01N33/564 ,  G01N33/577

Abstract: Tumor Necrosis Factor (TNF) Binding Protein is isolated and substantially purified. It has the ability to inhibit the cytotoxic effect of TNF and/or to maintain its prolonged beneficial effects. TNF Binding Protein II and salts, functional derivatives, precursors and active fractions thereof can be used to antagonize the deleterious effects of TNP and to prolong its beneficial effects Polyclonal and monoclonal antibodies to the TNF Binding Protein II are produced. They be used as pharmaceutical agents and in diagnostic assays.